Oncotelic Therapeutics, Inc.
OTLC
$0.056
-$0.0024-4.11%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 62.60% | 90.72% | -182.66% | -255.11% | -245.01% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -100.00% |
| Total Amortization of Deferred Charges | 0.92% | -86.07% | -91.18% | -84.72% | -78.76% |
| Total Other Non-Cash Items | -66.98% | -99.47% | 150.45% | 168.19% | 185.63% |
| Change in Net Operating Assets | -115.61% | -112.29% | -120.73% | -110.79% | 173.99% |
| Cash from Operations | 1.96% | -13.01% | -75.66% | 9.05% | 57.82% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 54.25% | 543.76% | 119.09% | 45.90% | -81.08% |
| Total Debt Repaid | -100.00% | -106.25% | -158.33% | -- | 159.15% |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 66.67% | -200.00% | -- | -- | -200.00% |
| Cash from Financing | -14.69% | 30.77% | 55.97% | 11.08% | -60.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -938.03% | 49.70% | -101.51% | 78.31% | -91.92% |